ISRCTN25330204已完成不适用
Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate®
Octapharma AG (Switzerland)0 个研究点目标入组 24 人开始时间: 2008年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female patients of any age
- •2. Suffering from congenital VWD
- •3. In need of replacement therapy with factor concentrate
- •4. Patients starting with a prophylactic treatment must have documentation of at least three apparently spontaneous bleeding episodes (any bleeding site and treated with factor concentrate) in the 6 months prior to enrolment
- •5. Patients switching from a prophylactic treatment with another factor concentrate to prophylaxis with Wilate® should have anamnesis of bleeds with respective documentation in the period of 12 months prior to enrolment
排除标准
- •1. Presence of a bleeding disorder other than VWD
- •2. History of non-compliance
- •3. Difficulties in achieving venous access that would prohibit prophylaxis
- •4. Incapability to follow the requirements of the surveillance, e.g. unable to keep a patient diary
研究者
相似试验
进行中（未招募）
1 期
Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate - WILCOMEEUCTR2008-000795-24-SEOctapharma AG30
招募中
Unknown
Follow-up study of the long-term efficacy and safety of investigator-initiated clinical trials (HUCV002-01-02 study and HUCV002-01-03 study) of intravenous HUCV002-01 in patients with chronic heart failure (HUCV002-01-02 study and HUCV002-01-03 study)chronic heart failureJPRN-jRCT1070220091Ide Tomomi30
招募中
不适用
ong-term prognosis follow-up study on prevention and treatment of COVID-19 patients with Traditional Chinese medicineITMCTR2100005478Institute of Basic Clinical Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences
招募中
1 期
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone DeficiencyIdiopathic Growth Hormone DeficiencyCTIS2023-504020-25-00umos Pharma Inc.69
进行中（未招募）
1 期
A follow-on study in patients who have received gene therapy for Beta-thalassemia in the TIGET-BTHAL study to assess safety and effectiveness of treatment.Beta-thalassemiaMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2017-001366-14-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT10